Journal article icon

Journal article

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Abstract:

PURPOSE: Targeted therapies using the anti-EGFR antibodies panitumumab (Pmab) or cetuximab (Cmab) are currently restricted to patients with metastatic colorectal adenocarcinoma whose tumours do not show a mutation in KRAS. However, recent retrospective studies indicated that patients with tumours mutated in codon 13 of KRAS may benefit from treatment with Cmab in contrast to patients with tumours mutated in KRAS codon 12. METHODS: To study the functional impact of the subtype of KRAS mutatio...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00432-012-1319-7

Authors


Messner, I More by this author
Cadeddu, G More by this author
Huckenbeck, W More by this author
Knowles, HJ More by this author
Gabbert, HE More by this author
Expand authors...
Journal:
Journal of cancer research and clinical oncology
Volume:
139
Issue:
2
Pages:
201-209
Publication date:
2013-02-05
DOI:
EISSN:
1432-1335
ISSN:
0171-5216
URN:
uuid:0516e9c0-80cb-4357-a8ec-4233962995de
Source identifiers:
354726
Local pid:
pubs:354726

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP